世界のインフルエンザNA阻害剤市場予測（～2028年）：ザナミビル、オセルタミビル、ペラミビル

• 英文タイトル：Global Influenza NA Inhibitor Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8855 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

インフルエンザNA阻害剤市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のインフルエンザNA阻害剤の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 インフルエンザNA阻害剤市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・ザナミビル、オセルタミビル、ペラミビル 用途別セグメントは次のように区分されます。 ・インフルエンザA型治療、インフルエンザB型治療 世界のインフルエンザNA阻害剤市場の主要な市場プレーヤーは以下のとおりです。 ・Green Cross、Roche、GlaxoSmithKline、Henan DaKen Chemical、ATK Chemical、Chemwill Asia Co.,Ltd.、Shionogi Co.、NeoPharm、Moksha8 Pharma 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、インフルエンザNA阻害剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なインフルエンザNA阻害剤メーカーの企業概要、2019年～2022年までのインフルエンザNA阻害剤の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なインフルエンザNA阻害剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別インフルエンザNA阻害剤の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までのインフルエンザNA阻害剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのインフルエンザNA阻害剤市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、およびインフルエンザNA阻害剤の産業チェーンを掲載しています。 ・第13、14、15章では、インフルエンザNA阻害剤の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Green Cross、Roche、GlaxoSmithKline、Henan DaKen Chemical、ATK Chemical、Chemwill Asia Co.,Ltd.、Shionogi Co.、NeoPharm、Moksha8 Pharma ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：ザナミビル、オセルタミビル、ペラミビル ・用途別分析2017年-2028年：インフルエンザA型治療、インフルエンザB型治療 ・インフルエンザNA阻害剤の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・インフルエンザNA阻害剤のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・インフルエンザNA阻害剤のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・インフルエンザNA阻害剤の南米市場規模2017年-2028年：ブラジル、アルゼンチン ・インフルエンザNA阻害剤の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Influenza NA Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Influenza NA Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Influenza A Treatment accounting for % of the Influenza NA Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Zanamivir segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Influenza NA Inhibitor include Green Cross, Roche, GlaxoSmithKline, Henan DaKen Chemical, and ATK Chemical, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Influenza NA Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Zanamivir
Oseltamivir
Peramivir
Market segment by Application can be divided into
Influenza A Treatment
Influenza B Treatment
The key market players for global Influenza NA Inhibitor market are listed below:
Green Cross
Roche
GlaxoSmithKline
Henan DaKen Chemical
ATK Chemical
Chemwill Asia Co.,Ltd.
Shionogi Co.
NeoPharm
Moksha8 Pharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Influenza NA Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Influenza NA Inhibitor, with price, sales, revenue and global market share of Influenza NA Inhibitor from 2019 to 2022.
Chapter 3, the Influenza NA Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Influenza NA Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Influenza NA Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Influenza NA Inhibitor.
Chapter 13, 14, and 15, to describe Influenza NA Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Influenza NA Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Influenza NA Inhibitor Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.3 Market Analysis by Application
1.3.1 Overview: Global Influenza NA Inhibitor Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Influenza A Treatment
1.3.3 Influenza B Treatment
1.4 Global Influenza NA Inhibitor Market Size & Forecast
1.4.1 Global Influenza NA Inhibitor Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Influenza NA Inhibitor Sales in Volume (2017-2028)
1.4.3 Global Influenza NA Inhibitor Price (2017-2028)
1.5 Global Influenza NA Inhibitor Production Capacity Analysis
1.5.1 Global Influenza NA Inhibitor Total Production Capacity (2017-2028)
1.5.2 Global Influenza NA Inhibitor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Influenza NA Inhibitor Market Drivers
1.6.2 Influenza NA Inhibitor Market Restraints
1.6.3 Influenza NA Inhibitor Trends Analysis
2 Manufacturers Profiles
2.1 Green Cross
2.1.1 Green Cross Details
2.1.2 Green Cross Major Business
2.1.3 Green Cross Influenza NA Inhibitor Product and Services
2.1.4 Green Cross Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Influenza NA Inhibitor Product and Services
2.2.4 Roche Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Influenza NA Inhibitor Product and Services
2.3.4 GlaxoSmithKline Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Henan DaKen Chemical
2.4.1 Henan DaKen Chemical Details
2.4.2 Henan DaKen Chemical Major Business
2.4.3 Henan DaKen Chemical Influenza NA Inhibitor Product and Services
2.4.4 Henan DaKen Chemical Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 ATK Chemical
2.5.1 ATK Chemical Details
2.5.2 ATK Chemical Major Business
2.5.3 ATK Chemical Influenza NA Inhibitor Product and Services
2.5.4 ATK Chemical Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Chemwill Asia Co.,Ltd.
2.6.1 Chemwill Asia Co.,Ltd. Details
2.6.2 Chemwill Asia Co.,Ltd. Major Business
2.6.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product and Services
2.6.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Shionogi Co.
2.7.1 Shionogi Co. Details
2.7.2 Shionogi Co. Major Business
2.7.3 Shionogi Co. Influenza NA Inhibitor Product and Services
2.7.4 Shionogi Co. Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 NeoPharm
2.8.1 NeoPharm Details
2.8.2 NeoPharm Major Business
2.8.3 NeoPharm Influenza NA Inhibitor Product and Services
2.8.4 NeoPharm Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Moksha8 Pharma
2.9.1 Moksha8 Pharma Details
2.9.2 Moksha8 Pharma Major Business
2.9.3 Moksha8 Pharma Influenza NA Inhibitor Product and Services
2.9.4 Moksha8 Pharma Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Influenza NA Inhibitor Breakdown Data by Manufacturer
3.1 Global Influenza NA Inhibitor Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Influenza NA Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Influenza NA Inhibitor
3.4 Market Concentration Rate
3.4.1 Top 3 Influenza NA Inhibitor Manufacturer Market Share in 2021
3.4.2 Top 6 Influenza NA Inhibitor Manufacturer Market Share in 2021
3.5 Global Influenza NA Inhibitor Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Influenza NA Inhibitor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Influenza NA Inhibitor Market Size by Region
4.1.1 Global Influenza NA Inhibitor Sales in Volume by Region (2017-2028)
4.1.2 Global Influenza NA Inhibitor Revenue by Region (2017-2028)
4.2 North America Influenza NA Inhibitor Revenue (2017-2028)
4.3 Europe Influenza NA Inhibitor Revenue (2017-2028)
4.4 Asia-Pacific Influenza NA Inhibitor Revenue (2017-2028)
4.5 South America Influenza NA Inhibitor Revenue (2017-2028)
4.6 Middle East and Africa Influenza NA Inhibitor Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Influenza NA Inhibitor Sales in Volume by Type (2017-2028)
5.2 Global Influenza NA Inhibitor Revenue by Type (2017-2028)
5.3 Global Influenza NA Inhibitor Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Influenza NA Inhibitor Sales in Volume by Application (2017-2028)
6.2 Global Influenza NA Inhibitor Revenue by Application (2017-2028)
6.3 Global Influenza NA Inhibitor Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Influenza NA Inhibitor Sales by Type (2017-2028)
7.2 North America Influenza NA Inhibitor Sales by Application (2017-2028)
7.3 North America Influenza NA Inhibitor Market Size by Country
7.3.1 North America Influenza NA Inhibitor Sales in Volume by Country (2017-2028)
7.3.2 North America Influenza NA Inhibitor Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Influenza NA Inhibitor Sales by Type (2017-2028)
8.2 Europe Influenza NA Inhibitor Sales by Application (2017-2028)
8.3 Europe Influenza NA Inhibitor Market Size by Country
8.3.1 Europe Influenza NA Inhibitor Sales in Volume by Country (2017-2028)
8.3.2 Europe Influenza NA Inhibitor Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Influenza NA Inhibitor Sales by Type (2017-2028)
9.2 Asia-Pacific Influenza NA Inhibitor Sales by Application (2017-2028)
9.3 Asia-Pacific Influenza NA Inhibitor Market Size by Region
9.3.1 Asia-Pacific Influenza NA Inhibitor Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Influenza NA Inhibitor Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Influenza NA Inhibitor Sales by Type (2017-2028)
10.2 South America Influenza NA Inhibitor Sales by Application (2017-2028)
10.3 South America Influenza NA Inhibitor Market Size by Country
10.3.1 South America Influenza NA Inhibitor Sales in Volume by Country (2017-2028)
10.3.2 South America Influenza NA Inhibitor Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Influenza NA Inhibitor Sales by Type (2017-2028)
11.2 Middle East & Africa Influenza NA Inhibitor Sales by Application (2017-2028)
11.3 Middle East & Africa Influenza NA Inhibitor Market Size by Country
11.3.1 Middle East & Africa Influenza NA Inhibitor Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Influenza NA Inhibitor Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Influenza NA Inhibitor and Key Manufacturers
12.2 Manufacturing Costs Percentage of Influenza NA Inhibitor
12.3 Influenza NA Inhibitor Production Process
12.4 Influenza NA Inhibitor Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Influenza NA Inhibitor Typical Distributors
13.3 Influenza NA Inhibitor Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---